Demos Could Result From ‘Most Favored Nation’ Order

The Trump administration’s long-awaited executive order that seeks to tie U.S. drug prices to costs in other countries may represent more presidential campaign talking points than real policy that will take effect quickly. But analysts expect that the overarching issue of drug pricing will stick around, regardless of which candidate wins on Nov. 3.

For example, the executive order signals that the administration could pursue price caps for select Medicare Part B and D drugs in a possible second term. The order calls for demonstration projects to test “most favored nation” pricing in Parts B and D.

© 2024 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

humana-logo-on-smartphone
February 22

CenterWell Pharmacy Exec: New App Targets Digitally Savvy Seniors

READ MORE
part-d-document-with-stethoscope
February 22

Part D ‘Copay Smoothing’ Rollout Might Be Bumpy, Some Experts Warn

READ MORE
pharmacist-looking-up-drug-information
February 22

Preventive Drug Lists Can Boost Workers’ Health, Study Suggests

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today